2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonic acid | 195517-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonic acid
• 英文别名: 4-Sulfo-2,3,5,6-tetrafluorophenol
• CAS: 195517-29-4
• 化学式: C₆H₂F₄O₄S
• 分子量: 246.139
• InChiKey: FVKRBXYHROENKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2,3,5,6-tetrafluoro-4-hydroxybenzenesulfonic acid 、 EP-2104-15 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 EP-2104-15-STP
  参考文献：
  名称：

  Optically pure and enriched isomers of chelating ligands and contrast agents

  摘要：

  有机螯合配体、有机螯合配体前体和金属螯合物被披露。还描述了合成它们的方法，包括制备光学富集或光学纯度组合物的方法。

  公开号：

  US20060155120A1

文献信息

• WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS
  申请人：COOPER EDWARD MICHAEL

  公开号：US20060239922A1

  公开（公告）日：2006-10-26

  Disclosed are cyanine dyes that are useful for labelling and detecting biological and other materials. The dyes are of formula (I): in which at least one of groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 R 11 , R 12 , R 13 and R 14 is -L-M or -L-P, where L is a linking group, M is a target bonding group and P is a conjugated component, and at least one of groups R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 comprises fluorine. The use of cyanine dyes substituted by fluorine and having additional substitution with three or more sulphonic acid groups for labelling biological target molecules results in a labelled product in which there is reduced dye-dye aggregation and improved photostability, compared with cyanine dyes having no such substitutions. The dyes of the present invention are particularly useful in assays involving fluorescence detection where continual or repeated excitation is a requirement, for example in kinetic studies, or in microarray analyses where microarray slides may need to be reanalysed over a period of days.

  揭示了一种对于标记和检测生物和其他材料有用的青霉素染料。该染料的化学式为（I）：其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和R14中的至少一个是-L-M或-L-P，其中L是连接基团，M是目标键合基团，P是共轭组分，并且R3、R4、R5、R6、R7、R8、R9和R10中的至少一个包含氟。通过用氟取代并具有三个或更多磺酸基团的青霉素染料标记生物靶分子，得到的标记产品中减少了染料-染料聚集并提高了光稳定性，与没有这种取代的青霉素染料相比。本发明的染料在涉及荧光检测的分析中特别有用，其中需要连续或重复激发，例如在动力学研究中，或在微阵列分析中，微阵列玻片可能需要在数天内重新分析。
• Photocleavable isotope-coded affinity tags
  申请人：Olejnik Jerzy

  公开号：US20050085630A1

  公开（公告）日：2005-04-21

  This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as proteins and protein fragments from biological samples from in vivo and in vitro sources. Agents comprise a detectable group bound to a photoreactive group. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals.

  本发明涉及可以用于检测和分离来自复杂混合物（如来自体内和体外源的生物样本中的蛋白质和蛋白质片段）的靶组分的试剂和结合物。试剂包括结合到光反应基团的可检测基团。结合物包括通过共价键结合到底物的试剂，这些共价键可以通过电磁辐射的施加而选择性地断裂。标记有可检测分子的目标物质可以很容易地从异源混合物中识别和分离出来。将结合物暴露于辐射会释放出目标物质以功能形式完全不变。使用光解分子前体作为结合物，标记可以被结合到大分子中，新生大分子被分离并标记完全去除。该发明还涉及使用这些结合物分离出的目标物质，这些目标物质可能作为药用剂或可用于给人类和其他哺乳动物的组合物。
• PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING
  申请人：Vision Global Holdings Ltd.

  公开号：US20140335018A1

  公开（公告）日：2014-11-13

  The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

  本发明提供了一种含有基于血红蛋白的治疗药物的药物组合物，用于治疗癌症。血红蛋白部分可以靶向癌细胞，治疗部分（即活性剂/治疗药物）可以高效地杀死癌细胞。本发明中使用的基于血红蛋白的治疗药物可用于治疗各种癌症，如胰腺癌、白血病、头颈癌、结直肠癌、肺癌、乳腺癌、肝癌、鼻咽癌、食管癌、前列腺癌、胃癌和脑癌。该组合物可单独使用或与其他治疗剂（如化疗剂）结合使用，对癌症治疗产生协同作用，抑制转移和/或减少复发。目前申请的基于血红蛋白的5FU-双染料共轭物和/或基于血红蛋白的5FU-单染料共轭物也可用于活细胞成像和诊断成像。
• [EN] MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF<br/>[FR] COMPOSÉS DE THIÉNOAZÉPINE SUPPORTÉS PAR DES MACROMOLÉCULES ET LEURS UTILISATIONS
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2021081402A1

  公开（公告）日：2021-04-29

  The invention provides macromolecule-supported compounds of Formula I comprising a macromolecular support linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The invention further provides methods of treating cancer with the macromolecule-supported compounds.

  该发明提供了一种由大分子支持物质和一种或多种噻吩氮杂环庚烷衍生物通过共轭连接而形成的化合物，其化学式为I。该发明还提供了一种包含具有反应性功能基团的噻吩氮杂环庚烷衍生物中间体组合物。这种中间体组合物适用于通过连接物或连接基团形成大分子支持化合物的底物。该发明还提供了使用这种大分子支持化合物治疗癌症的方法。
• [EN] THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF<br/>[FR] IMMUNOCONJUGUÉS DE THIÉNOAZÉPINE ET LEURS UTILISATIONS
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2021081407A1

  公开（公告）日：2021-04-29

  The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

  本发明提供了公式I的免疫结合物，包括通过共轭连接与一种或多种噻唑烷衍生物相连的抗体。该发明还提供了噻唑烷衍生物中间体组合物，包括反应性功能基团。这种中间体组合物适合用作通过连接物或连接基团形成免疫结合物的底物。本发明还提供了使用这些免疫结合物治疗癌症的方法。